The company will organize a virtual event for investors on Monday, November 15

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) – Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer patients, announced today that the Society for Cancer Immunotherapy Communication Committee (SITC) has selected an abstract presenting preclinical data from the Company’s FT538 and FT573 programs for presentation at the SITC 2021 Annual Meeting press conference. selected titled “Ready-to-use, iPSC-derived NK cells induce potent cytotoxic activity against primary glioblastoma cells and promote long-term, sustainable survival in vivoWill be presented by Jeffrey S. Miller, MD, Professor of Medicine, University of Minnesota and Associate Director, Masonic Cancer Center. The press conference will take place on Wednesday, November 10 from 12:30 p.m. to 2 p.m. ET.

Dr. Miller’s presentation will describe the anti-tumor activity of the Company’s FT538 clinical product candidate as monotherapy and in combination with an NK cell activator targeting B7-H3, an immune checkpoint transmembrane protein overexpressed in many cancer cells. human and generally associated with a poor prognosis. The presentation will also describe the integration of a novel chimeric antigen receptor (CAR) construct targeting B7-H3 into the main induced pluripotent stem cell (iPSC) line of FT538 to create the preclinical product candidate from the company FT573, a CAR targeted at B7-H3. NK cell incorporating multiple anti-tumor modalities.

In a recently peer-reviewed article in Stem cell entitled “Harnessing the characteristics of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”, FT538 has been shown to share metabolic, transcriptional and functional characteristics with adaptive NK cells, a rare subset of NK cells with memory-like properties that have a genome-wide epigenetic profile and response. parallel boost to CD8 + T cytotoxic effector cells. Published data demonstrate that FT538 exhibits significantly improved serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its new modified components, including CD38 knockout and expression of the IL-15 / IL-15R fusion protein, which have been shown to enhance metabolic form, increase resistance to oxidative stress and induce a protein expression program that enhances NK cell activation and effector function. Studies in the Stem cell These publications were conducted as a collaboration between scientists at Fate Therapeutics and Dr. Miller’s lab, and were led by Frank Cichocki, Ph.D., University of Minnesota.

Investor Event Webcast and Conference Call

The company will host a live audio webcast on Monday, November 15, 2021 at 4:30 p.m. ET to highlight its emerging pipeline of ready-to-use, multiplexed and iPSC-derived NK cell programs for the treatment of solid tumors. To participate in the conference call, please dial (877) 303-6235 (national) or (631) 291-4837 (international) and refer to Conference ID 2793475. The live webcast can be accessed under ” Events and Presentations ”in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website approximately two hours after the event.

About Fate Therapeutics’ iPSC Product Platform
The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables the mass production of homogeneous, ready-to-use cellular products that can be administered in multiple doses to provide more effective pharmacological activity, including in combination with other cancer treatments. Human iPSCs possess the unique properties of unlimited self-renewal and differentiation potential in all cell types of the body. The company’s unique approach is to design human iPSCs as part of a one-time genetic modification event and select a single designed iPSC for maintenance as the iPSC clonal master line. Analogous to the master cell lines used to make biopharmaceutical pharmaceuticals such as monoclonal antibodies, iPSC clonal master lines are a renewable source for the manufacture of cell therapy products that are well defined and uniform in composition, can be mass produced at large scale in a cost-effective manner, and can be delivered off the shelf for patient treatment. As a result, the Company’s platform is uniquely capable of overcoming the many limitations associated with the production of cell therapies using cells from patients or donors, which is logistically complex and expensive and is subject to batch processing. batch and cell to cell variability that may affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is backed by an intellectual property portfolio of more than 350 issued patents and 150 pending patent applications.

About FT538
FT538 is an experimental, universal, ready-to-use natural killer (NK) cancer immunotherapy derived from a master clonal induced pluripotent stem cell line (iPSC) designed with three functional components: a novel high affinity 158V CD16 , non-cleavable (hnCD16) Fc receptor, which has been modified to prevent its downregulation and to enhance its binding to tumor-targeting antibodies; a fusion of the IL-15 receptor (IL-15RF) which increases the activity of NK cells; and deletion of the CD38 gene (CD38KO), which promotes persistence and function in high oxidative stress environments. FT538 is designed to enhance innate immunity in cancer patients, where endogenous NK cells are generally decreased in number and function due to previous treatment regimens and tumor suppressor mechanisms. In preclinical studies, FT538 showed superior effector function of NK cells, compared to peripheral blood NK cells, with the potential to confer significant anti-tumor activity in patients through multiple mechanisms of action. FT538 is being investigated in a Phase 1 multidose clinical trial for the treatment of acute myeloid leukemia (AML) and in combination with daratumumab, a monoclonal antibody therapy targeting CD38, for the treatment of multiple myeloma (NCT04614636). FT538 is also being investigated in a Phase 1 multidose clinical trial in association with one of several tumor-targeting monoclonal antibodies for the treatment of advanced solid tumors (NCT05069935).

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-class cellular immunotherapies for cancer patients. The Company has established a leading position in the clinical development and manufacture of ready-to-use universal cellular products using its proprietary Induced Pluripotent Stem Cell (iPSC) product platform. The Company’s immuno-oncology portfolio includes commercially available natural killer (NK) and T cell product candidates, which are designed to synergize with well-established cancer therapies, including point inhibitors. immune control and monoclonal antibodies, and to target tumor associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, California. For more information, please visit www.fatetherapeutics.com.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s clinical studies and pre-clinical research and development programs, its ongoing and planned clinical studies, and the safety and therapeutic potential of the company’s product candidates. These forward-looking statements and all other forward-looking statements contained in this press release are based on management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially. and unfavorably to those stated or implied by such forward-looking statements. forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s product candidates do not demonstrate the safety or efficacy required to obtain regulatory approval or to justify further development, the risk that the results observed in previous studies of the Company’s product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, the risk of delay or difficulties in the manufacture of the Company’s product candidates or in the launch of, or the recruitment of patients in any clinical study, the risk that the Company ceases or delays the preclinical or clinical development of any of its product candidates for various reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, the amount and type of data to be generated, or otherwise to support regulatory approval, difficulties or delays in recruiting patients and the continuation of the Company’s current and planned clinical trials, difficulties in manufacturing or supplying product candidates from Company for clinical trials, and any adverse event or other negative outcome that may be observed during preclinical or clinical development), and the risk that its product candidates may not provide therapeutic benefit or may cause other unforeseen adverse effects . For a discussion of other risks and uncertainties, and other important factors, each of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the periodic filings. from the Company to the Securities and Exchange Commission, including, but not limited to, the latest periodic report filed by the Company, and from time to time in Company press releases and other communications with investors. Fate Therapeutics is providing the information in this press release as of this date and assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Contact:
Christina tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]